Search results
Showing 946 to 960 of 2184 results for guidelines
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)
Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
Cardiovascular disease prevention: risk assessment (general population) (IND269)
This indicator covers the percentage of people aged 45 to 84 years who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
Our recommendations on the use of highly specialised technologies are made by an independent advisory committee
MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)
Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.
Tell us what matters to you, your organisation or your community.